Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Shares Outstanding (Weighted Average): 2016-2024

Historic Shares Outstanding (Weighted Average) for Apellis Pharmaceuticals (APLS) over the last 9 years, with Dec 2024 value amounting to $124.4 million.

  • Apellis Pharmaceuticals' Shares Outstanding (Weighted Average) rose 3.71% to $126.3 million in Q3 2025 from the same period last year, while for Jun 2025 it was $125.7 million, marking a year-over-year increase of 3.56%. This contributed to the annual value of $124.4 million for FY2024, which is 4.97% up from last year.
  • Apellis Pharmaceuticals' Shares Outstanding (Weighted Average) amounted to $124.4 million in FY2024, which was up 4.97% from $118.5 million recorded in FY2023.
  • In the past 5 years, Apellis Pharmaceuticals' Shares Outstanding (Weighted Average) registered a high of $124.4 million during FY2024, and its lowest value of $75.7 million during FY2020.
  • In the last 3 years, Apellis Pharmaceuticals' Shares Outstanding (Weighted Average) had a median value of $118.5 million in 2023 and averaged $117.8 million.
  • Data for Apellis Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY increased of 26.67% (in 2022) over the last 5 years.
  • Yearly analysis of 5 years shows Apellis Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $75.7 million in 2020, then increased by 15.26% to $87.3 million in 2021, then rose by 26.67% to $110.6 million in 2022, then climbed by 7.17% to $118.5 million in 2023, then rose by 4.97% to $124.4 million in 2024.